To further understand whether the expression level of IMPDH1 is associated with the prognosis of tumor patients receiving immunotherapy, we analyzed the differences in therapeutic response and prognosis among IMPDH1 expression subgroups in three cohorts of patients receiving immunotherapy for non-small cell lung cancer (Figures 7A, B), urothelial cell carcinoma (Figures 7C, D), and renal clear cell carcinoma (Figures 7E, F). Here, IMPDH1 is linked to non-small cell lung carcinoma.